强直性脊柱炎（ankylosing spondylitis, AS）是主要侵犯骶髂关节、脊柱及临近肌腱、软组织的慢性自身免疫性疾病。AS的典型病理演变含免疫炎症驱动应答、骨破坏与新骨形成等环节，这些环节在同一部位反复发作，最终导致关节逐渐僵直变形。此文从IL-17在AS中的致病机制、调控作用以及研究现状等方面进行论述，阐明IL-17作为靶点在AS治疗中的优势，为IL-17相关药物的开发以及AS的治疗奠定基础。

Ankylosing spondylitis (AS) is a chronic autoimmune disease that primarily affects the sacroiliac joints, spine and adjacent tendons, soft tissues. The typical pathological progression of AS involves processes such as immune inflammation-driven responses, bone destruction, and new bone formation. These processes recur at same sites, ultimately leading to gradual joint stiffness and deformation. This article discusses the pathogenic mechanism， regulatory role, and current research status of IL-17 in AS, aiming to clarify the advantages of IL-17 as target in AS treatment and lay foundation for the development of IL-17-related drugs and the clinical management of AS.